


Interests Register

Lung cancer Advisory Committee

Publication Date: 21/01/2019


Name	Role with NICE	Type of interest	Description of interest	R	Relevant date	es	Comments
				Interest arose	Interest declared	Interest ceased	
Gary McVeigh	Committee Chair	None	N/A	N/A	N/A	N/A	No action
Douglas West From February 2018 Vice-chair from April 2018	Committee Vice- Chair Thoracic Surgeon	Direct financial (non-specific)	Fees, and travel expenses received from Johnson and Johnson for acting as faculty on a number of sessions for spinal surgeons (ongoing).	Mar 2014	Dec 2017		No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline.
Douglas West From February 2018 Vice-chair from April 2018	Committee Vice-Chair Thoracic Surgeon	Direct financial (non-specific)	Fees, and travel/accommodation expenses received from Medtronic, for teaching surgical teams how to perform thoracoscopic (VATS) lobectomy operations.	Apr 2017	Dec 2017	Apr 2018	No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline.



Douglas West From February 2018 Vice-chair from April 2018	Committee Vice- Chair Thoracic Surgeon	Direct Financial (non-specific)	Fee received from Astra Zeneca. For talks on stage 3 lung cancer, Clinical Expert Group on Immunotherapy for non- small lung cancer	Nov 2017	Dec 2017	No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline.
Douglas West From February 2018 Vice-chair from April 2018	Committee Vice-Chair Thoracic Surgeon	Direct non- financial (non- specific)	Part of a panel for Public Health England to support the writing of a report; Perspectives in Lung Cancer Care (organisation of lung cancer services and identifying areas of best practice in Europe that could be applied to the NHS.). Bristol Myers Squibb will pay travel expenses for the 3 meetings	Apr 2018	Apr 2018	No action other than the process of open declaration. Will not focus on specific treatments or drugs covered in the lung cancer guideline update.
Shahzeena Aslam	Committee member Clinical Oncologist	Direct financial	Attended British thoracic oncology group conference in Dublin from 24th -26th January 2018. Pfizer have agreed to pay conference fee	Jan 2018	Feb 2018	No action other than the process of open declaration – non-commercial activity.




Shahzeena Aslam	Committee member Clinical Oncologist	Direct financial (non-specific)	Attended Prostate cancer summit in London, 23rd and 24th Feb 2018 Sponsored by Janssen for travel, accommodation and conference fee.	Feb 2018	Mar 2018	No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline.
Shahzeena Aslam	Committee member Clinical Oncologist	Direct non- financial	Attended a meeting sponsored by BMS in Cambridge exploring clinical cases of lung cancer treated with nivolumab	Mar 2018	Apr 2018	No action other than the process of open declaration
Shahzeena Aslam	Committee member Clinical Oncologist	Direct non- financial	Attended a British Thoracic Oncology Group neuroendocrine/small cell lung cancer essential update meeting 18/04/18. Free event.	Apr 2018	May 2018	No action other than the process of open declaration
Shahzeena Aslam	Committee member Clinical Oncologist	Direct non- financial	Attendance at Oncology Forum meeting June 2018, Liverpool. Covers general oncology updates, with one session dedicated to lung cancer management. Nothing covered in the meeting, is covered by the guideline update. (Flights and	Jun 2018	Jun 2018	No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline.




			accommodation. No registration fee). Organised by UK Oncologists and sponsored by a number of pharmacological companies, predominantly Novartis, Health care at Home.				
Elaine Borg	Committee member Pathologist	Direct financial	Honorarium received for lecture at EBUS masterclass. Event hosted by UCLH and sponsored by AstraZeneca	Oct 2017	Dec 2017	Oct 2018	Related to RQ1.2 & RQ1.2 (GComm2, 4.12.17) declaration not made until after the committee meeting. Exclude from any future recommendation making for RQ1.2 & RQ1.2
Elaine Borg	Committee member Pathologist	Direct financial	Honorarium received for lecture at EBUS masterclass June 2018	Jun 2018	May 18		Related to RQ1.2 & RQ1.2 Exclude from any future recommendation making for RQ1.2 & RQ1.2
Lynn Campbell	Committee member Medical Oncologist	Direct financial (non- specific)	Payment from Pfizer for delivering a presentation: 'Presentation of first-line Crizotinib data'.	Feb 2017	July 2017	Feb 2018	No action other than the process of open declaration




						Not specific to any topic covered in the scope of the guideline. Crizotinib is one of the cancer TA drugs which is in the chemotherapy algorithm
Lynn Campbell	Committee member Medical Oncologist	Direct non- financial (non- specific)	Attended an evening meeting sponsored by Roche about immunotherapy on the 3 rd May 2018. General info about immunotherapy drugs in practice. Refreshments provided	May 2018	May 2018	No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline.
Lynn Campbell	Committee member Medical Oncologist	Direct non- financial (non- specific)	Attendance at Oncology Forum meeting, Liverpool, June 2018. Covers general oncology updates, with one session dedicated to lung cancer management. Nothing covered in the meeting, is covered by the guideline update. (Flights and accommodation. No registration fee). Organised by UK Oncologists and sponsored by a number of pharmacological	Jun 2018	Jun 2018	No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline.




			companies, predominantly Novartis, Health care at Home.			
Steve Connor From May 2018	Committee member Neuroradiologist	Direct Financial (non- specific)	Receives payment for work in private hospitals. Paid directly. 95% of private practice fees from HCA insurance. 1/6 of the working week is spent in private practice. Private practice is for general neuroradiology imaging and none in relation to lung cancer.	2002	Apr 2018	No action other than the process of open declaration
Steve Connor From May 2018	Committee member Neuroradiologist	Non-financial (non- specific)	Research collaborations with head and neck oncology groups, in regards to head and neck cancer treatment. Not related to the scope of this guideline update.	2012	Apr 2018	No action other than the process of open declaration
Sujal Desai	Committee member Radiologist	Direct non- financial (non- specific)	DMC Radiology Reporting Ltd partner. The company does not provide any imaging services. Provides outsourcing teleradiology for the NHS and private sector. No financial remuneration received.	Aug 2005	Oct 2017	No action other than the process of open declaration. The imaging studies cover all body regions and pathologies – there is no specific focus on



							chest or to any area ne guideline.
Sujal Desai	Committee member Radiologist	Direct financial	Taught courses/workshops (not lung cancer), in Hong Kong and Beijing for IDKD. The topics were; interstitial lung diseases, airways diseases and mediastinal and hilar disorders. Flight and accommodation paid, honorarium received.	2017	Oct 2017	prod decl IDK prov payi	action other than the cess of open aration D is the course rider therefore ment is non imercial
Sujal Desai	Committee member Radiologist	Direct financial (non- specific)	Attended a meeting by Pfizer, for the launch of their antifungal drug Isavuconazole. Paid an honorarium and travel costs.	Nov 2017	Dec 2017	prod decl Not cove	ection other than the cess of open aration. specific to any topic ered in the scope of guideline.
Sujal Desai	Committee member Radiologist	Direct non- financial (non- specific)	Speaking at a European Congress of Radiology in Vienna. Conference on smoking related interstitial lung diseases (not lung cancer related), Conference fee wavered, travel and accommodation.	Mar 2018	Feb 2018	prod decl Not cove	action other than the cess of open aration. specific to any topic ered in the scope of guideline.



			•			•
Sujal Desai	Committee member Radiologist	Direct financial (non- specific)	Run an educational course for Boehringer Ingelheim, on interstitial lung diseases. Honorarium and travel costs will be paid	June 18	June 18	No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline.
Jesme Fox	Committee member Lay member	Direct non- financial professional and personal	Medical Director of Roy Castle Lung Cancer Foundation. The organisation receives grants from pharmaceutical companies as part of its funding. Does not exceed 6% of their income	1998	Jul 2017	No action other than the process of open declaration
Jesme Fox	Committee member Lay member	In direct financial	Presented at a number of conferences and participated in several advisory boards, organised by pharmaceutical companies. Honorarium paid to employer.	1998	Jul 2017	No action other than the process of open declaration
Jesme Fox	Committee member Lay member	In direct financial (non-specific)	Attended an Advisory Board meeting for Takeda. Honorarium paid to employer. Travel and accommodation paid.	Jan 2018	Jan 2018	No action other than the process of open declaration.



			Donation given to employer			Not specific to any topic covered in the scope of the guideline.
Jesme Fox	Committee member Lay member	Non-financial professional and personal	Paper by O'Dowd was discussed at previous meeting/GCom2. Charity employer, Roy Castle Lung Cancer Foundation funded Dr O'Dowd's 3 year Clinical Research Fellowship post at Nottingham University (2013 to 2015). The research paper discussed was one of several she undertook and published during this time.	2013	Feb 2018	No action other than the process of open declaration
Jesme Fox	Committee member Lay member	Direct non- financial (non- specific)	Participated in a short Advisory Board teleconference 08.04.18, with Boehringer Ingelheim. No honorarium or expenses were paid. The topics discussed were not relevant to Committee discussions (non-medical interventions).	Apr 2018	Apr 2018	




		T	1	T	1	
Jesme Fox	Committee member Lay member	Direct non- financial (non- specific)	31st May, attended a Global Oncology Advocacy Leaders Meeting in Chicago. Travel and accommodation expenses paid by Bristol- Myers Squibb. The topics discussed general cancer issues, not relevant to lung cancer guideline.	May 2018	Jun 2018	No action other than the process of open declaration. Reasonable travel and subsistence. Not specific to any topic covered in the scope of the guideline.
Tom Haswell	Committee member Lay member	Direct financial, personal	National Cancer Research Institute (NCRI) – Lung studies group. Attend 2 meetings a year, receives an honorarium.		Oct 2017	No action other than the process of open declaration – non-commercial activity.
Tom Haswell	Committee member Lay member	Non-financial professional and personal	Steering Committee member of the British Thoracic Oncology Group. Attended the annual conference where British Thoracic Oncology Group paid travel and accommodation.	2014	Feb 2018	No action other than the process of open declaration - reasonable travel and subsistence
Sue Maughn	Committee member Commissioner	Direct financial	United Kingdom - lung cancer coalition - speaker on sustainability	Apr 2018	Mar2018	No action other than the process of open declaration



			and transformation partnerships in the commissioning of best practice lung cancer services				reasonable travel and subsistence
Andrea McIver	Committee member Nurse	Direct non- financial (non- specific)	Attended the National lung nurse forum for nurses (NLCFN) workshop 14th & 15th May. Accommodation and refreshments provided by NLCFN.	May 2018	May 2018	N/A	Direct non-financial (non-specific) Not specific to any topic covered in the scope of the guideline
Neal Navani	Committee member Respiratory Physician	Direct financial, personal	Honorarium received for lecture at EBUS masterclass in October 2017. Event hosted by UCLH and sponsored by AstraZeneca.	Oct 2017	Apr 2017	Oct 2018	RQ 1.1 & RQ 1.2 (GComm2) Not involved in making recommendations
Neal Navani	Committee member Respiratory Physician	Direct non- financial	Chairing "global advisory board" March 2017, for Astra Zeneca. Travel arranged, no honorarium received.	Mar 2017	Apr 2017	Mar 2018	No action other than the process of open declaration reasonable travel and subsistence
Neal Navani	Committee member Respiratory Physician	Direct non- financial	Travel and conference registration from MSD to attend World Lung	Dec 2016	Apr 2017	Dec 2017	No action other than the process of open declaration




			Cancer conference Dec 2016			reasonable travel and subsistence
Neal Navani	Committee member Respiratory Physician	Direct financial	Investigator on Lung boost trail (published 2015). Study funded by MRC and included salary payment for 3 years.	2008	Oct 2017	Paper to be included as evidence for RQ 1.1 & RQ 1.2 (GComm2) Not involved in making recommendations
Neal Navani	Committee member Respiratory Physician	Direct financial	Private practice, same scope as NHS work (except, do not prescribe any treatments).	Apr 2017 for company	Dec 2017	RQ 1.1 & RQ 1.2 (GComm2) Not involved in making recommendations
			Set up as a limited company, income from private practice, is managed via the company. Private income mainly via insurers, on a fee basis.			Only procedure related to the guideline carried out in private practice is EBUS
			Includes carrying out EBUS procedures (approx 10 per week on the NHS and 1 per week privately			
Neal Navani	Committee member Respiratory Physician	In direct financial	Attended an advisory board (Lung cancer related, but not on any of the topics being covered		Dec 2017	No action other than the process of open declaration




			in the guideline): Honoraria will be paid into the employer's research account.			
Neal Navani	Committee member Respiratory Physician	In direct financial	Attended optimising outcomes in lung cancer meeting in Rome, accommodation & travel paid for by AZ. Honorarium paid to research account	Nov 2017	Dec 2017	No action other than the process of open declaration - reasonable travel and subsistence
Neal Navani	Committee member Respiratory Physician	In direct financial (non-specific)	Attending in March 2018, EBUS Re-biopsy class Cardiff. Honorarium paid to employer. Astra Zeneca to pay expenses, and travel	Mar 2018	Dec 2017	No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline.
Neal Navani	Committee member Respiratory Physician	Direct financial, personal (non- specific)	Speaking at event in, Slovenia, at the European Society of Thoracic surgery (ESTS), on the cost-effectiveness of lung cancer screening. ESTS paying conference registration fee, expenses and accommodation.	May 2018	Dec 2017	No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline.



Neal Navani	Committee member Respiratory Physician	Committee member Respiratory Physician	Attended European Endoscopy Forum meeting in Hamburg, accommodation & travel paid for by Olympus.		Dec 2017		No action other than the process of open declaration reasonable travel and subsistence
Neal Navani	Committee member Respiratory Physician	Committee member Respiratory Physician	May 2018 Presented at the American Thoracic Society Conference; 'Interventional Pulmonology' in San Diego. Travel and accommodation paid by Oncimmune Ltd. No payment received.	May 2018	May 2018		
Marco Scarci Resigned October 2017	Committee member Thoracic Surgeon	None	N/A	N/A	N/A	N/A	No action
Michael Snee Resigned October 2017	Committee member Clinical Oncologist	Direct non- financial	Attended world lung cancer conference, Vienna – received hospitality from Astra Zeneca (dinner)	Dec 2016	Mar 2017	Dec 2017	No action other than the process of open declaration reasonable travel and subsistence



							Resigned October 2017
Michael Snee Resigned October 2017	Committee member Clinical Oncologist	Direct financial	Paid work for (Quintiles IMS) clinical research organisation. Involves analysis of anonymous data that has been collected from patients including lung cancer patients with an emphasis on recurrence, toxicity and death. Data collected will be "real world" data from patients not enrolled in clinical trials but undergoing pharmacological treatment with licensed drugs.		Jul 2017		No action
David Waller From December 2017 Resigned January 2018	Committee member Thoracic Surgeon	None	N/A	N/A	N/A	N/A	No action From December 2017 Resigned January 2018
Rhiannon Walters-Davies	Committee member Pharmacist	Direct non- financial	Travel and conference paid by Boehringer, for American Society of	Jun 2017	Oct 2017	Jun 2018	No action other than the process of open declaration




			Clinical Oncology conference				reasonable travel and subsistence
Rhiannon Walters-Davies	Committee member Pharmacist	Direct non- financial	Travel and conference paid by Pierre Fabre, for British Thoracic Oncology Group conference	Jan 2017	Oct 2017	Jan 2018	No action other than the process of open declaration reasonable travel and subsistence
Rhiannon Walters-Davies	Committee member Pharmacist	Direct non- financial	Travel and conference paid by Ipsen, for British Oncology Pharmacy Association conference	Oct 2017	Oct 2017		No action other than the process of open declaration reasonable travel and subsistence
Rhiannon Walters-Davies	Committee member Pharmacist	In direct financial (non-specific)	5th Prostate Forum Wales- 11th December, education event sponsored by Astellas. Honorarium paid to pharmacy education endowment fund at Velindre (not the budget holder for the fund).	Dec 2017	Jan 2018		No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline.



	1		•	1		
Rhiannon Walters-Davies	Committee member Pharmacist	In direct financial (non-specific)	Attended an AZ education event Osimertinib Audit Honorarium paid to education budget where I am not the budget holder.		Feb 2018	No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline.
Rhiannon Walters-Davies	Committee member Pharmacist	In direct financial (non-specific)	Attended a Roche education event, on Pharmacist prescribing immunotherapies Honorarium paid to education budget (not the budget holder). Travel and accommodation paid.		Feb 2018	No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline.
Rhiannon Walters-Davies	Committee member Pharmacist	Direct non- financial personal and professional	Written an article on advances in lung cancer, for pharmacy journal, pending publication	Feb 2018	Feb 2018	No action other than the process of open declaration
Rhiannon Walters-Davies	Committee member Pharmacist	Direct non- financial (non- specific)	Attended a meeting on how to horizon forecast for upcoming drugs (all drugs not yet approved). The meeting was held in March 2018 supported by the Association of the	Mar 18	May 18	No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline.




			British Pharmaceutical Industry.			
Rhiannon Walters-Davies Rhiannon Walters-Davies	Committee member Pharmacist Committee member Pharmacist	In direct financial (non- specific) In direct financial	Attend an advisory board, for Astra Zeneca, 5th July 2018, on Durvalumab. Accommodation, travel and accommodation expenses paid. Honorarium paid to education fund. The topics discussed, were not relevant to lung cancer guideline. Attend an internal meeting (educational) for Boehringer, 26th June 2018, on Afatanib. Honorarium paid to education fund. Accommodation, travel and accommodation expenses paid.	Jun 18	Jul 18	No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline. No action other than the process of open declaration.
Rhiannon Walters-Davies	Committee member Pharmacist	Direct non- financial (non- specific)	Attendance at Oncology Forum meeting June 2018, Liverpool. Covers general oncology updates, with one session dedicated to lung cancer management. Nothing covered in the meeting, is covered by	Jun 18	Jun 18	No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline



			the guideline update. (Flights and accommodation. No registration fee). Organised by UK Oncologists and sponsored by a number of pharmacological companies, predominantly Novartis, Health care at Home.				
Nigel Westwood	Committee member Lay member	None	N/A	N/A	N/A	N/A	No action
Clifford Wyn Jones	Committee member GP	Direct financial (non-specific)	Assessor for Palliative (paid) Medicine Diploma – Cardiff University	Jan 2017	Jun 2017	Apr 2017	No action other than the process of open declaration. Not specific to any topic covered in the scope of the guideline.
Clifford Wyn Jones	Committee member GP	Direct financial	Framework for Cancer, National GP lead (paid role). An NHS post funded by Macmillan Cancer Support	Jul 2015	Jun 2017		No action other than the process of open declaration Non-commercial

GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER



Relevant dates: Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has

ceased to hold shares or undertake relevant private practice.